Sign In
Buy BCYC
$4.20
-0.1000 (-2.33%)
At Close: Jun 03, 2026
Why Bicycle Therapeutics Stock Raced Ahead Today
06:40pm, Thursday, 13'th Jul 2023
The U.K.-based biotech announced a fresh offering of its ADSes. It's seeking to net around $187 million in proceeds with the issue.
Bicycle Therapeutics: Not Much Differentiation Between Bicycles And mAbs Yet
07:16am, Sunday, 14'th May 2023
BCYC's distinction is that it is founded by a Nobel laureate. However, unless it can differentiate its product's efficacy from that of mAbs, that may be its only distinction.
Wall Street Analysts Think Bicycle Therapeutics PLC Sponsored ADR (BCYC) Could Surge 146.31%: Read This Before Placing a Bet
11:26am, Thursday, 04'th May 2023
The consensus price target hints at a 146.3% upside potential for Bicycle Therapeutics PLC Sponsored ADR (BCYC). While empirical research shows that this sought-after metric is hardly effective, an up
Bicycle (BCYC) up on Collaboration With Novartis for Conjugates
09:59am, Wednesday, 29'th Mar 2023
Bicycle (BCYC) and Novartis enter into a collaboration agreement to develop, manufacture and commercialize conjugate drugs for several oncology indications. Stock soars following the news.
CAMBRIDGE, England, & BOSTON--( BUSINESS WIRE )--Bicycle Therapeutics plc (NASDAQ:BCYC), a biotechnology company pioneering a new and differentiated class of therapeutics based on its proprietary bicy
CAMBRIDGE, England, & BOSTON--(BUSINESS WIRE)--Bicycle Therapeutics plc (NASDAQ:BCYC), a biotechnology company pioneering a new and differentiated class of therapeutics based on its proprietary bicycl
Bicycle Therapeutics to Participate in the Morgan Stanley 20th Annual Global Healthcare Conference
07:00am, Tuesday, 06'th Sep 2022
CAMBRIDGE, England, & BOSTON--(BUSINESS WIRE)--Bicycle Therapeutics plc (NASDAQ: BCYC), a biotechnology company pioneering a new and differentiated class of therapeutics based on its proprietary bicyc
Bicycle Therapeutics: Promising Early-Stage Cancer Drug Developer
12:03pm, Tuesday, 05'th Jul 2022
BCYC was founded by a Nobel Prize winner. Hopefully, that will not be its only claim to fame.
Bicycle Therapeutics reports promising BT8009 study results, shares tank 30%
08:38am, Tuesday, 12'th Apr 2022
Bicycle Therapeutics plc (NASDAQ: BCYC) is down 30% after the biotech firm pioneering novel and differentiated therapeutics class based on its bicyclin peptide tech announced preliminary first phase r
Here's Why Bicycle Therapeutics Stock Looks Ill Today
11:57am, Monday, 11'th Apr 2022
Lackluster clinical trial results for its lead candidate are to blame.
Bicycle Therapeutics PLC Sponsored ADR (BCYC) Stock Jumps 24.5%: Will It Continue to Soar?
09:02am, Monday, 11'th Apr 2022
Bicycle Therapeutics PLC Sponsored ADR (BCYC) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't sugges
Bicycle Therapeutics shares fall 23% after the company shares interim Phase 1 data
07:41am, Monday, 11'th Apr 2022
Shares of Bicycle Therapeutics Inc. BCYC, +24.54% tumbled 23.4% in premarket trading on Monday after the company shared interim data from a Phase 1 clinical trial for its urothelial-cancer treatment.
Why Bicycle Therapeutics Stock Is Soaring Today
03:07pm, Friday, 08'th Apr 2022
Bicycle Therapeutics plc (NASDAQ: BCYC) has announced interim Phase 1 results from the Phase 1/2 trial of BT8009, a second-generation BTC targeting Nectin-4, in patients with advanced solid tumors.
Bicycle Therapeutics to Present Interim BT8009 Phase I Clinical Trial Results at the 2022 AACR Annual Meeting
01:00pm, Friday, 08'th Apr 2022
CAMBRIDGE, England & BOSTON--(BUSINESS WIRE)--Bicycle Therapeutics plc (NASDAQ: BCYC), a biotechnology company pioneering a new and differentiated class of therapeutics based on its proprietary bicycl
Vir Biotechnology, Inc. (VIR) Moves 14.8% Higher: Will This Strength Last?
07:10pm, Thursday, 31'st Mar 2022 Zacks Investment Research
Vir Biotechnology, Inc. (VIR) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further streng
